Wilson highlights franchise runway. “KOMZIFTI generated $2.1 million in net product revenue in the final weeks of 2025. Although it’s early, the launch is off to a strong start,” said Troy Wilson, President and Chief Executive Officer. “Importantly, KOMZIFTI is now listed in the FDA’s Orange book with patent protection through July 2044. That runway strengthens the long-term value of the franchise, particularly as we expand into frontline AML and combination settings.” Wilson emphasized the company’s strategic positioning: “Across relapsed/refractory and frontline AML, we estimate the total US opportunity at approximately $7 billion.” Chief Commercial Officer Brian Powl added: “We’re also thrilled to report that certain Blue plans are now requiring patients to go on KOMZIFTI before allowing coverage for the other approved menin inhibitor. It’s our understanding that their decision to implement this step edit was based on the efficacy, safety and predictable price per patient.”
Payer step edits signal differentiation. Li Watsek from Cantor Fitzgerald asked about the step edit policy, prompting Powl to elaborate: “Our understanding is the basis of that is built on a report from a group called IPD Analytics. It’s an independent consulting firm who is influential to many payers and their recent reports of the relapsed/refractory market in evaluating KOMZIFTI recommended this step edit for adult patients with relapsed/refractory NPM1-mutant AML.” Powl noted the annual wholesale acquisition cost for KOMZIFTI is approximately $600,000 versus nearly $1 million for the competitor menin inhibitor due to different dosing schemas. Roger Song from Jefferies inquired about patient demand trends, to which Powl responded: “The launch has, as I said, has been off to a very strong start. We are seeing patient demand. The feedback we’ve heard from physicians has echoed back the differentiation pillars that we’ve talked about.”
Multiple 2026 catalysts outlined. Management provided specific guidance for collaboration revenue: $45 million to $55 million in 2026, $90 million to $110 million in 2027, and $90 million to $110 million in 2028. Chief Medical Officer Mollie Leoni detailed the clinical roadmap: “We expect to present updated intensive chemotherapy data from KOMET-007 in the first half of 2026,” and “Updated data will be presented in the second half of this year” for the darlifarnib-cabozantinib combination in renal cell carcinoma. The company initiated Phase 1b dose expansion of darlifarnib with cabozantinib and plans to present preliminary data from the darlifarnib-adagrasib combination in KRAS G12C-mutated tumors in the first half of 2026. Enrollment continues in the pivotal KOMET-017 frontline AML trials across approximately 200 global sites, with topline results anticipated in 2028.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.